We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > STORM CHASER

News List

STORM CHASER Trial Fails to Meet Primary Endpoint in Post-Exposure Prevention of Symptomatic COVID-19 americanpharmaceuticalreview
June 17, 2021
AstraZeneca announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
Matrix Collaborates with AstraZeneca on Trial for COVID-19 Long-Acting Antibody Combination americanpharmaceuticalreview
February 09, 2021
Matrix Medical Network® announced a collaboration with AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19.
Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial contractpharma
January 27, 2021
Care Access to provide decentralized, mobile research site operations for AstraZeneca’s AZD7442 Phase III trial in the U.S.